Columbus, OH 的 B細胞淋巴瘤 臨床試驗
7 項針對 B細胞淋巴瘤 的研究正在 Columbus（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
招募中3 期
- Ohio State University Comprehensive Cancer Center, Columbus
- Ohio Health Research Institute, Columbus
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
招募中2 期
- Ohio State University Medical Center Dept. of Internal Medicine, Division of Hematology, Columbus
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
招募中2 期
- Research Site, Columbus
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
招募中1/2 期
- Research Site, Columbus
DALY II USA/ MB-CART2019.1 for DLBCL
招募中2 期
- The Ohio State University Wexner Medical Center James Cancer, Columbus
A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma
招募中
- Ohio State University Comprehensive Cancer Center, Columbus
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
招募中1 期
- Nationwide Children's Hospital, Columbus
其他城市的 B細胞淋巴瘤 試驗
- New York City, NY19 項研究
- Houston, TX16 項研究
- Chicago, IL12 項研究
- Nashville, TN11 項研究
- Philadelphia, PA11 項研究
- Rochester, MN10 項研究
- Baldwin Park, CA9 項研究
- Milwaukee, WI9 項研究
- Cleveland, OH9 項研究
- Salt Lake City, UT8 項研究
- Boston, MA8 項研究
- Pittsburgh, PA7 項研究
Columbus 的其他研究
- 非小細胞肺癌56 項研究
- 乳癌39 項研究
- 卵巢癌39 項研究
- 癌症（所有類型）38 項研究
- 肺癌37 項研究
- 急性髓系白血病35 項研究
- 慢性淋巴性白血病28 項研究
- 轉移性癌症27 項研究
- 子宮內膜癌25 項研究
- 大腸直腸癌24 項研究
- 前列腺癌24 項研究
- 多發性骨髓瘤24 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。